ChromaDex Launches Tru Niagen® with iHerb, the World's Number One Online Destination for Health and WellnessBusiness Wire • 08/08/23
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023Business Wire • 08/02/23
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising EffectsBusiness Wire • 07/18/23
ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy AgingBusiness Wire • 06/16/23
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023Business Wire • 05/02/23
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023Business Wire • 03/06/23
Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 03/01/23
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023Business Wire • 02/27/23
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor SpaceBusiness Wire • 02/22/23
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) PatientsBusiness Wire • 01/31/23
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial BiogenesisBusiness Wire • 01/17/23
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)Business Wire • 01/12/23
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative BiomarkersBusiness Wire • 12/27/22
Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a TurnaroundZacks Investment Research • 12/19/22